TICKERNERD
Menu
NKTRNKTRHealthcare · Biotechnology

NKTR Stock Forecast: Nektar Therapeutics Price Predictions for 2026-2027

Last close, 18 Sept 2026
$67
−1.84% on the day

The 12 Wall Street analysts covering Nektar Therapeutics hold a median 12-month price target of $151 — +124.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 18 Sept 2026 — in the upper half.

Market cap
$2.3B
Ticker Nerd rank
51 / 100
Median analyst target
$151
Analysts covering
12
Revenue$10.1M−9.3% y/y
Operating income−$41.8M
Net income−$40.6M
Free cash flow−$75.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−8.9%
YTD
+58.7%
1Y
+14.2%
From 52W high
−33.1%
From 52W low
+91.1%
$35
$100
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NKTR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nektar Therapeutics on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Sept 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
80
Revisions
74
Quality
70
Growth
54
Issuance
50
Value
49
Size
34
Volatility
18
Accruals
11

Momentum (80): The shares have been drifting up relative to others.

Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NKTR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NKTR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26NKTRHigh $192Median $151Low $65

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $65Median $151High $192

The green dot is the last close — the median target sits +124.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Sept 2026BTIGReiteratesBuy$178
9 Sept 2026BTIGReiteratesBuy$178
21 Aug 2026JP MorganReinstatesNeutral$65
22 July 2026Canaccord GenuityInitiatesBuy$153
22 July 2026Canaccord GenuityInitiatesBuy—
11 May 2026WedbushMaintainsNeutral—
11 May 2026WedbushMaintainsNeutral$95 → $80
8 May 2026Piper SandlerMaintainsOverweight—
8 May 2026Piper SandlerMaintainsOverweight$105 → $192
21 Apr 2026CitigroupMaintainsBuy—
21 Apr 2026WedbushMaintainsNeutral—
20 Apr 2026BTIGMaintainsBuy—
20 Apr 2026HC Wainwright & Co.MaintainsBuy—
24 Mar 2026WedbushInitiatesNeutral—
17 Mar 2026TD CowenInitiatesBuy—
16 Mar 2026CitigroupMaintainsBuy—
23 Feb 2026B. Riley SecuritiesReiteratesBuy—
10 Feb 2026BTIGMaintainsBuy—
10 Feb 2026HC Wainwright & Co.MaintainsBuy—
29 Jan 2026BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NKTR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NKTR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Nektar Therapeutics returned +14.2% against +16.3% for the S&P 500, dividends included.

NKTR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26NKTRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NKTR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Nektar Therapeutics (NKTR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.9×

Cheaper than 91% of US stocks

Price / sales
42.0×

Cheaper than 6% of US stocks

Price / book
2.5×

Cheaper than 37% of US stocks

EV / EBITDA
−13.4×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
−9.3%

Higher than 16% of US stocks

Earnings growth (YoY)
−9.3%

Higher than 27% of US stocks

Gross margin
—
Operating margin
−412.2%

Higher than 8% of US stocks

Net margin
−287.8%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−35.8%

Higher than 25% of US stocks

Return on assets
−12.5%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nektar Therapeutics (NKTR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nektar Therapeutics has a market value of $2.3B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $54.6M. The latest quarter shrank 9.3% year on year.

  • Net income over the same four quarters: −$157.1M, a −287.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−6.70.

  • Free cash flow in the twelve months to 30 June 2026: −$234.0M.

  • Shares outstanding: 34.1M.

  • Trailing P/E: −6.9×; forward P/E: −6.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Nektar Therapeutics employs 63 people — $866K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

NKTR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NKTRNektar Therapeutics$2.3B
51
AUPHAurinia Pharmaceuticals, Inc.$2.2B
94
GENBGenerate Biomedicines, Inc.$2.2B
1
PVLAPalvella Therapeutics, Inc.$2.2B
32
SLSSELLAS Life Sciences Group, Inc.$2.3B
64
TRVITrevi Therapeutics, Inc.$2.1B
53
OCULOcular Therapeutix, Inc.$2.1B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nektar Therapeutics — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NKTR news & analysis

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 28 Aug 2026neutral

Nektar Therapeutics announced that on August 20, 2026, its Organization and Compensation Committee granted non-qualified stock options for 25,200 common shares and 5,000 restricted stock units to eleven newly-hired employees under the company's 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — NKTR watchers may note the equity awards as a sign of hiring and talent attraction, though the announcement is a routine disclosure of inducement grants and carries no direct business impact.

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

PRNewsWire · 25 Aug 2026positive

Nektar Therapeutics announced publication in The Lancet of peer-reviewed results from the 16-week induction period of the global, randomized, double-blind, placebo-controlled Phase 2b REZOLVE-AD trial of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis. The study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA.

Why it matters — The positive Phase 2b results support continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD program, a key upcoming catalyst for Nektar.

Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming

Seeking Alpha · 14 Aug 2026positive

Seeking Alpha reaffirms a Strong Buy rating on Nektar Therapeutics, citing REZPEG's late-stage development for atopic dermatitis and alopecia areata. The Phase 3 ZENITH AD program, comprising three pivotal studies in moderate-to-severe AD subpopulations, is underway with topline data expected by mid-2028.

Why it matters — NKTR watchers would care because REZPEG's Phase 3 program is positioned as a key upcoming catalyst with a differentiated mechanism aimed at long-term disease control and safety advantages in a large global AD market.

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Zacks Investment Research · 14 Aug 2026neutral

Nektar Therapeutics reported second-quarter earnings that beat analyst estimates, though revenues fell short of expectations. Investor attention remains focused on rezpeg as late-stage studies advance in autoimmune diseases.

Why it matters — NKTR watchers would care because the mixed quarterly results combine with the late-stage progress of rezpeg, the key program driving near-term investor focus.

Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of Nektar Therapeutics' Q2 2026 earnings call, covering the company's quarterly results and management commentary. The item is the full earnings call transcript for the second quarter of 2026.

Why it matters — The transcript gives NKTR watchers direct access to management's discussion of the company's latest quarterly performance and outlook.

FAQ

Frequently asked questions about NKTR stock

What is the NKTR stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Nektar Therapeutics have a median 12-month price target of $151, with estimates ranging from $65 to $192. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NKTR stock a buy right now?

Of the 12 analysts covering Nektar Therapeutics, 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nektar Therapeutics 51 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NKTR?

As at 18 Sept 2026, Nektar Therapeutics ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (80 of 100).

Will NKTR stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +124.3% from the last close, and Ticker Nerd's factor model ranks Nektar Therapeutics 51 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NKTR stock forecast for 2030?

No analyst covering Nektar Therapeutics publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NKTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $192 over the next 12 months.

How has NKTR stock performed over the past year?

Nektar Therapeutics returned +14.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nektar Therapeutics do?

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes.

What is the latest news on NKTR?

The most recent item we track (PRNewsWire, 28 Aug 2026): "Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Nektar Therapeutics announced that on August 20, 2026, its Organization and Compensation Committee granted non-qualified stock options for 25,200 common shares and 5,000 restricted stock units to eleven newly-hired employees under the company's 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Nektar Therapeutics.

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes. The company also advances additional candidates across autoimmune, fibrotic, and cancer-related areas, including programs targeting ulcerative colitis, vitiligo, multiple sclerosis, and solid tumors. Through its proprietary chemistry and immunology expertise, Nektar Therapeutics develops highly selective therapeutic candidates intended to modulate key biological pathways and support precision treatment approaches across specialty disease areas.

CEO Mr. Howard W. Robin · 63 employees · United States · https://www.nektar.com